About NextFerm
NextFerm is a company based in Yokneam Illit (Israel) founded in 2013. NextFerm offers products and services including ProteVin™, Maximmune, AstaFerm®, NextFreeze™, and Biofuel. NextFerm operates in a competitive market with competitors including Nuevolution, Protalix BioTherapeutics, Lutris Pharma, Curesponse and Colbar LifeScience, among others.
- Headquarter Yokneam Illit, Israel
- SectorsHealthcareAgriculture
- Email••••••••
- Phone•••• ••••
- Website nextferm.com
- Social LinkedIn Facebook
- Legal Name Nextferm Technologies Ltd.
- Annual Revenue$159 K (USD)-21.28as on Dec 31, 2025
- Net Profit-$3.14 M (USD)49.17as on Dec 31, 2025
- EBITDA-$1.12 M (USD)72.96as on Dec 31, 2025
- Latest Funding Round$55.99K (USD), Grant
Dec 2019
- InvestorsEuropean Union
& 1 more
Products & Services of NextFerm
NextFerm offers a comprehensive portfolio of products and services, including ProteVin™, Maximmune, AstaFerm®, NextFreeze™, and Biofuel.
Fermented protein that enhances food flavor and nutritional value.
Fermentation-based product for immune support in nutrition.
Fermented ingredient used for health and food applications.
Technology for preserving food through fermentation methods.
Fermentation-derived biofuel for sustainable energy use.
Funding Insights of NextFerm
- Total Rounds 2
- Last Round Grant — $55,993
- First Round $54,958
(Sep 2019)
- Investors Count 2
All 2 funding rounds of NextFerm with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2019 | $55,993 | Grant | – | – | |
| Sep 2019 | $54,958 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in NextFerm
NextFerm has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | – | eicfund.eu | Brussels, Belgium | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for NextFerm
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of NextFerm
2 people are tracked at NextFerm (1 in leadership, 1 in board & advisors).
| Name | Role | Group |
|---|---|---|
Moran Gendelman (Bahalul) | Founder & CSO | Leadership |
Yossi Peled | Chairman | Board & advisors |
Complete people profiles for NextFerm
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of NextFerm
NextFerm is a publicly listed company on the TASE with ticker symbol NXFR.M in Israel, operating in the Consumer non-durables sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date26 Jan 2021
- Listed onTASE: NXFR.M
- Listed entityNextFerm Technologies Ltd.
- Exchange sectorConsumer non-durables
- ISINIL0011719338
- Share price2,500.00 ILA · 2026-10-12
- Market capitalisation8,446,975.00 ILA
- EPS (diluted, trailing year)-2.54 ILA
- Volume (last session)480
Financials of NextFerm
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 507,040 ILS | -10.0M ILS | -3.6M ILS |
| 2024 | 644,090 ILS | -19.7M ILS | -13.2M ILS |
| 2023 | 1.0M ILS | -15.7M ILS | -14.0M ILS |
| 2022 | 880,300 ILS | -27.1M ILS | -25.7M ILS |
| 2021 | 781,690 ILS | -17.8M ILS | -13.5M ILS |
Detailed financial statements for NextFerm
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of NextFerm
4 dated milestones of NextFerm across 8 years, from founding to its latest funding, stage changes and deals.
- Founded NextFerm is founded.
- Funding First funding round of $55K.
- Funding Latest funding round, Grant, of $56K.
- IPO Lists on the stock exchange (IPO).
Competitors of NextFerm
NextFerm operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nuevolution, Protalix BioTherapeutics, Lutris Pharma, Curesponse and Colbar LifeScience, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| nuevolution.com | 2001 | Copenhagen, Denmark | $12.45M | – | Drug treatments for oncology and chronic inflammatory diseases are developed. | |
| protalix.com | 1993 | Karmiel, Israel | – | – | Recombinant proteins are developed via a plant cell-based expression system. | |
| lutris-pharma.com | 2016 | Tel Aviv, Israel | $30M | – | Provider of anti-cancer therapy | |
| curesponse.com | 2018 | Rehovot, Israel | $14M | – | Provider of a tissue culture system to analyze cancer growth and drug response | |
| colbar.com | 1995 | Herzliya, Israel | $28.45M | – | Collagen-based products for tissue regeneration and dental applications are developed. | |
| oticpharma.com | 2008 | Yehud, Israel | $4.3M | – | Therapeutic products for ENT disorders are developed via FoamOtic technology. | |
| smzyme.com | 2013 | Herzliya Pituach, Israel | $4M | – | Proprietary protein engineering technology is developed for diabetes products. | |
| transpharma-medical.com | 2000 | Lod, Israel | $18M | – | Manufactures drug-products that utilizes transdermal drug delivery technology | |
| minoviatx.com | 2011 | Tirat Carmel, Israel | – | – | Cell therapy for mitochondrial diseases is provided via proprietary MAT. | |
| intecpharma.com | 2003 | Jerusalem, Israel | $5M | – | Develops drug delivery technologies to enhance treatments for Parkinson's, insomnia, and ulcers. |
Detailed competitors of NextFerm
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nextferm
Complete news archive for NextFerm
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to NextFerm
10 companies that operate in the same segment as NextFerm (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about NextFerm
NextFerm was founded in 2013 and raised its 1st funding round 6 years after it was founded.
NextFerm is headquartered in Yokneam Illit, Israel. It is registered at Yokneam Illit, North District, Israel.
Annual revenue of NextFerm is $159K as on Dec 31, 2025.
The company was founded in 2013 and is located in Yokneam Illit, Israel. Non-GMO proprietary technology is utilized to develop improved microorganisms, focusing on yeast strains. Operations target the fermented ingredients sector, with solutions intended for food, dietary supplements, brewing, and animal feeds. Development efforts emphasize natural, non-genetically modified approaches to enhance microbial performance in these markets.
NextFerm's top competitors include Protalix BioTherapeutics, Lutris Pharma and Minovia Therapeutics.
NextFerm offers ProteVin™, Maximmune, AstaFerm®, NextFreeze™, and Biofuel.
Yes, NextFerm is publicly traded on TASE under the ticker symbol NXFR.M.
NextFerm has 2 investors. Key investors include European Union, and EIC Fund.
NextFerm operates through Nextferm Technologies.